{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:34:56Z","timestamp":1792146896387,"version":"4.4.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1053\/j.seminhematol.2012.01.008","type":"journal-article","created":{"date-parts":[[2012,3,24]],"date-time":"2012-03-24T11:29:50Z","timestamp":1332588590000},"page":"120-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Eosinophilic Myeloid Disorders"],"prefix":"10.1053","volume":"49","author":[{"given":"Pierre","family":"Noel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2012.01.008_bib1","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2174\/138945007779940124","article-title":"Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders","volume":"8","author":"Reiter","year":"2007","journal-title":"Curr Drug Targets"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib3","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/0008-5472.CAN-04-4263","article-title":"The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2","volume":"65","author":"Reiter","year":"2005","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib4","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/sj.leu.2404266","article-title":"FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation","volume":"20","author":"Vu HA","year":"2006","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib5","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-03-343426","article-title":"Response of ETV6-FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3","volume":"118","author":"Walz","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib6","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib7","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3324\/haematol.2009.016345","article-title":"Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis","volume":"95","author":"Erben","year":"2010","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib8","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.jaci.2006.02.042","article-title":"Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report","volume":"117","author":"Klion","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaci.2010.03.042","article-title":"Refining the definition of hypereosinophilic syndrome","volume":"126","author":"Simon","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib10","series-title":"World Health Organization classification of tumours","first-page":"68","article-title":"Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1","author":"Bain BJ","year":"2008"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib11","series-title":"World Health Organization classification of tumours","first-page":"51","article-title":"Chronic eosinophilic leukaemia, not otherwise specified","author":"Bain BJ","year":"2008"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib12","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.leukres.2008.11.016","article-title":"Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1\/PDGFRA fusion and PDGFRA translocations","volume":"33","author":"Fink","year":"2009","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib13","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/sj.leu.2404154","article-title":"Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia","volume":"20","author":"Score","year":"2006","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib14","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.leu.2404662","article-title":"Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma","volume":"21","author":"Metzgeroth","year":"2007","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib15","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood-2010-05-286757","article-title":"Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease","volume":"117","author":"Elling","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib16","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2008.287","article-title":"Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias","volume":"22","author":"Gotlib","year":"2008","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib17","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00392-010-0144-8","article-title":"Cardiac manifestation of the hypereosinophilic syndrome: new insights","volume":"99","author":"Kleinfeldt","year":"2010","journal-title":"Clin Res Cardiol"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.rmed.2010.09.011","article-title":"Lung involvement in hypereosinophilic syndromes","volume":"105","author":"Dulohery","year":"2011","journal-title":"Respir Med"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib19","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/sj.leu.2404977","article-title":"The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus","volume":"21","author":"Burgstaller","year":"2007","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib20","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.leu.2403313","article-title":"Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias","volume":"18","author":"Vandenberghe","year":"2004","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib21","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib22","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib23","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2003-07-2393","article-title":"Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes","volume":"102","author":"Pitini","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib24","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2169\/internalmedicine.39.350","article-title":"Measurement of serum concentrations of cardiac troponin T in patients with hypereosinophilic syndrome: a sensitive non-invasive marker of cardiac disorder","volume":"39","author":"Sato","year":"2000","journal-title":"Intern Med"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib25","first-page":"9","article-title":"Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate","volume":"3","author":"Schaller","year":"2001","journal-title":"Med Gen Med"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib26","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(02)08505-7","article-title":"Treatment of hypereosinophilic syndrome with imatinib mesilate","volume":"359","author":"Gleich","year":"2002","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib27","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0145-2126(02)00046-2","article-title":"Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate","volume":"26","author":"Ault","year":"2002","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib28","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib29","doi-asserted-by":"crossref","first-page":"10700","DOI":"10.1073\/pnas.162140299","article-title":"Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop","volume":"99","author":"Roumiantsev","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib30","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2008.07033.x","article-title":"A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients","volume":"141","author":"Helbig","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib31","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","article-title":"Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia","volume":"109","author":"Jovanovic","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib32","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1182\/blood-2007-07-100164","article-title":"Relapse following discontinuation of imatinib mesylate therapy for FIP1L1\/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing","volume":"110","author":"Klion","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib33","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","article-title":"The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome","volume":"92","author":"Baccarani","year":"2007","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib34","first-page":"546","article-title":"[Successful treatment with low-dose dasatinib in a patient with chronic eosinophilic leukemia intolerant to imatinib]","volume":"52","author":"Imagawa","year":"2011","journal-title":"Rinsho Ketsueki"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.leukres.2010.08.004","article-title":"Low-dose nilotinib can maintain complete molecular remissions in FIP1L1\/PDGFRA-positive hypereosinophilic syndrome","volume":"35","author":"Tabouret","year":"2011","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib36","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaci.2007.11.027","article-title":"Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia","volume":"121","author":"Simon","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib37","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/onc.2010.476","article-title":"The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro","volume":"30","author":"von Bubnoff","year":"2011","journal-title":"Oncogene"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib38","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/leu.2011.181","article-title":"Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation","volume":"26","author":"Metzgeroth","year":"2012","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib39","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/leu.2009.2","article-title":"FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib","volume":"23","author":"Lierman","year":"2009","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib40","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/leu.2010.145","article-title":"Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene","volume":"24","author":"Nishioka","year":"2010","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib41","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/sj.bmt.1705437","article-title":"Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript","volume":"38","author":"Halaburda","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib42","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.bmt.1703379","article-title":"Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome","volume":"29","author":"Juvonen","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib43","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2141.2002.03771.x","article-title":"Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome","volume":"119","author":"Ueno","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib44","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s002770050018","article-title":"Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration","volume":"79","author":"Schoffski","year":"2000","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib46","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2007.03.015","article-title":"Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance","volume":"120","author":"Bohm","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib47","first-page":"3","article-title":"Mastocytosis (mast cell disease)","volume":"51","author":"Horny","year":"2008"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib48","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2007.05.024","article-title":"KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1\/PDGFRA-associated chronic eosinophilic leukemia are distinct entities","volume":"120","author":"Maric","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib49","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","article-title":"Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation","volume":"77","author":"Golub","year":"1994","journal-title":"Cell"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib50","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib51","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000046641","article-title":"Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor beta","volume":"107","author":"Steer","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib52","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":"CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins","volume":"90","author":"Carroll","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib53","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.leukres.2009.03.011","article-title":"Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors","volume":"33","author":"Nand","year":"2009","journal-title":"Leuk Res"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib54","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood.V86.2.834.bloodjournal862834","article-title":"Myeloproliferative disorder associated with 8p11 translocations","volume":"86","author":"Aguiar","year":"1995","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib55","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.humpath.2009.11.003","article-title":"8p11 myeloproliferative syndrome: a review","volume":"41","author":"Jackson","year":"2010","journal-title":"Hum Pathol"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib56","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/blood.V93.4.1381","article-title":"The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1","volume":"93","author":"Popovici","year":"1999","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib57","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/sj.thj.6200561","article-title":"Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases","volume":"5","author":"Vizmanos","year":"2004","journal-title":"Hematol J"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib58","doi-asserted-by":"crossref","first-page":"14479","DOI":"10.1073\/pnas.0404438101","article-title":"PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder","volume":"101","author":"Chen","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib59","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1182\/blood-2002-03-0947","article-title":"Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia","volume":"101","author":"Matsushima","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib60","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1002\/cncr.25036","article-title":"Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes","volume":"116","author":"Wimazal","year":"2010","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2012.01.008_bib61","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2010-08-258772","article-title":"The renaissance of interferon therapy for teh treatment of myeloid malignancies","volume":"117","author":"Kiladjian JJ","year":"2011","journal-title":"Blood"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196312000091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196312000091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:21:08Z","timestamp":1758522068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196312000091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0037196312000091"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2012.01.008","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eosinophilic Myeloid Disorders","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2012.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}